The UK has signed agreements to buy 90 million doses of vaccines in development to treat COVID-19 by drugmakers including Pfizer Inc, BioNTech SE and Valneva SE.
The British government yesterday said that it has secured access to three different vaccine candidates and it is setting up a program seeking 500,000 volunteers to participate in clinical trials.
Pfizer and BioNTech plan to supply 30 million doses of their vaccine candidate this year and next, the companies said.
Photo: AFP
The companies plan to seek approval as early as October and could produce as many as 100 million doses by the end of this year.
The UK described the order as that alliance’s first binding agreement with any government.
The US has been supporting Pfizer and BioNTech’s efforts through its US$10 billion Operation Warp Speed research program. The vaccine uses a novel technology called messenger RNA (mRNA).
Valneva agreed to supply 60 million doses of a shot that it is developing. The UK previously struck a supply agreement for a vaccine being tested by AstraZeneca PLC with the University of Oxford.
The UK also said that it ordered treatments containing antibodies that neutralize COVID-19 from AstraZeneca.
Valneva, a French drugmaker, would supply a further 40 million doses if its vaccine is found to be safe, effective and suitable, the UK said.
The company is producing the vaccine at a factory in Livingston, Scotland.
Valneva said it expects the government to help fund clinical studies and it is negotiating funding to expand the Livingston facility.
Separately, Britain’s GlaxoSmithKline PLC (GSK) said that it would invest £130 million (US$163 million) to buy a 10 percent stake in Germany’s CureVac AG, launching a collaboration to develop up to five mRNA-based vaccines with technology already being used by the biotech company to develop a COVID-19 vaccine.
CureVac’s existing COVID-19 mRNA and rabies vaccines research programs are not included in the deal, the companies said.
CureVac, based in Tuebingen and backed by the Bill & Melinda Gates Foundation, last month said that it would start human trials of an experimental vaccine for treating COVID-19 in the country.
Additional reporting by Reuters
Apple Inc has closed in on an agreement with OpenAI to use the start-up’s technology on the iPhone, part of a broader push to bring artificial intelligence (AI) features to its devices, people familiar with the matter said. The two sides have been finalizing terms for a pact to use ChatGPT features in Apple’s iOS 18, the next iPhone operating system, said the people, who asked not to be identified because the situation is private. Apple also has held talks with Alphabet Inc’s Google about licensing its Gemini chatbot. Those discussions have not led to an agreement, but are ongoing. An OpenAI
ASML Holding NV’s new advanced chip machines have a daunting price tag, said Taiwan Semiconductor Manufacturing Co (TSMC, 台積電), one of the Dutch company’s biggest clients. “The cost is very high,” TSMC senior vice president Kevin Zhang (張曉強) said at a technology symposium in Amsterdam on Tuesday, referring to ASML’s latest system known as high-NA extreme ultraviolet (EUV). “I like the high-NA EUV’s capability, but I don’t like the sticker price,” Zhang said. ASML’s new chip machine can imprint semiconductors with lines that are just 8 nanometers thick — 1.7 times smaller than the previous generation. The machines cost 350 million euros (US$378 million)
INSATIABLE: Almost all AI innovators are working with the chipmaker to address the rapidly growing AI-related demand for energy-efficient computing power, the CEO said Taiwan Semiconductor Manufacturing Co (TSMC, 台積電) yesterday reported about 60 percent annual growth in revenue for last month, benefiting from rapidly growing demand for artificial intelligence (AI) and high-performance computing applications. Revenue last month expanded to NT$236.02 billion (US$7.28 billion), compared with NT$147.9 billion in April last year, the second-highest level in company history, TSMC said in a statement. On a monthly basis, revenue surged 20.9 percent, from NT$195.21 billion in March. As AI-related applications continue to show strong growth, TSMC expects revenue to expand about 27.6 percent year-on-year during the current quarter to between US$19.6 billion and US$20.4 billion. That would
‘FULL SUPPORT’: Kumamoto Governor Takashi Kimura said he hopes more companies would settle in the prefecture to create an area similar to Taiwan’s Hsinchu Science Park The newly elected governor of Japan’s Kumamoto Prefecture said he is ready to ensure wide-ranging support to woo Taiwan Semiconductor Manufacturing Co (TSMC, 台積電) to build its third Japanese chip factory there. Concerns of groundwater shortages when TSMC’s two plants begin operations in the prefecture’s Kikuyo have spurred discussions about the possibility of tapping unused dam water, Kumamoto Governor Takashi Kimura said in an interview on Saturday. While Kimura said talks about a third plant have yet to occur, Bloomberg had reported TSMC is already considering its third Japanese fab — also in Kumamoto — which would make more advanced chips. “We are